Luis A. Rojas
Expertise in
13
conditions

Dr. Luis A. Rojas

Oncology
1000 E 23rd St, Suite 350, 
Sioux Falls, SD 
Accepting New Patients
Offers Telehealth
Expertise in
13
conditions
1000 E 23rd St, Suite 350, 
Sioux Falls, SD 

Overview

Luis A. Rojas, MD, provides gynecologic oncology services at Avera Medical Group Gynecologic Oncology in Sioux Falls, SD.

Dr. Rojas is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Malignant Mixed Mullerian Tumor, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, and Hernia Surgery.

Dr. Rojas is board certified in American Board Of Obstetrics And Gynecology; Board Certified In Gynecologic Oncology. He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 5 clinical trials. Dr. Rojas is currently accepting new patients.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in OH

Board Certifications

American Board Of Obstetrics And Gynecology; Board Certified In Gynecologic Oncology

Fellowships

Cleveland Clinic Foundation, Cleveland, OH, Gynecologic Oncology

Hospital Affiliations

Avera St Mary's Hospital
Avera Marshall Regional Medical Ctr
Avera Queen Of Peace
Avera Mckennan Hospital & University Health Center
Spencer Municipal Hospital

Languages Spoken

English
French
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Avera Health
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 11 Less Insurance Carriers -

Locations

Avera Medical Group Gynecologic Oncology — Prairie Center
1000 E 23rd St, Suite 350, Sioux Falls, SD 57105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: August 04, 2026
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
Enrollment Status: Unknown
Publish Date: January 25, 2022
Intervention Type: Biological, Drug, Other
Study Drugs: Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide Phosphate, Paclitaxel
Study Phase: Phase 2
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 4 Less Clinical Trials

7 Total Publications

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.
Journal: Gynecologic oncology
Published: March 04, 2026
Similar Doctors
Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Avera Medical Group Gynecologic Oncology — Prairie Center

1000 E 23rd St, Suite 350, 
Sioux Falls, SD 
 (0.1 miles away)
605-322-7535
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. David Starks is a gynecologic oncologist at Avera Medical Group Gynecologic Oncologist. Dr. Starks is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Vulvar Cancer, Ovarian Cancer, and Cervical Cancer. Dr. Starks is currently accepting new patients.

Expertise in
52
conditions
Dr. Vinod Parameswaran
Hematology | Oncology
Expertise in
52
conditions
Dr. Vinod Parameswaran
Hematology | Oncology
Referral may be required

Avera Medical Group Hematology

1000 E 23rd St Ste 200, 
Sioux Falls, SD 
 (1.4 miles away)
605-322-3035
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vinod Parameswaran is a Hematologist and an Oncologist practicing medicine in Sioux Falls, South Dakota. Dr. Parameswaran is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, Thrombocytopenia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Parameswaran is currently accepting new patients.

Expertise in
69
conditions
Expertise in
69
conditions
Referral may be required

Avera Cancer Institute — Sioux Falls

1000 E 23rd St, Suite 340, 
Sioux Falls, SD 
 (0.1 miles away)
605-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Benjamin M. Solomon, MD, is an expert in medical oncology at Avera Medical Group Oncology & Hematology in Sioux Falls, SD. Dr. Solomon is highly rated in 69 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Neuroendocrine Tumor, Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration. Dr. Solomon is board certified in American Board Of Internal Medicine Certifications: Internal Medicine Hematology Medical Oncology. Dr. Solomon is currently accepting new patients.

Frequently Asked Questions about Dr. Luis A. Rojas

How do I make an appointment with Dr. Luis A. Rojas?

You can book an appointment with Dr. Luis A. Rojas by calling their office at 605-322-7535. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Luis A. Rojas a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Luis A. Rojas is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Luis A. Rojas specialize in?

While Dr. Luis A. Rojas is a Oncology, they have specific expertise in Ovarian Cancer, Malignant Mixed Mullerian Tumor, and Virilizing Ovarian Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Luis A. Rojas participate in research or clinical trials?

Yes. Dr. Luis A. Rojas has published 7 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Luis A. Rojas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Luis A. Rojas accept my insurance?

Dr. Luis A. Rojas accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 605-322-7535 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rojas's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile